<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067363</url>
  </required_header>
  <id_info>
    <org_study_id>MOR107-C001</org_study_id>
    <nct_id>NCT03067363</nct_id>
  </id_info>
  <brief_title>First in Human Single Ascending Dose Study of MOR107</brief_title>
  <official_title>Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alan Richardson</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LanthioPep BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first in human study of MOR107. It is a 2 part, single centre, double-blind,
      randomised, placebo-controlled study in healthy male subjects. Part 1 is a single ascending
      dose study, and Part 2 is a parallel group, dose range finding study in healthy male subjects
      on a low sodium diet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MOR107 is an angiotensin 2 receptor (AT2R) agonist with the potential to treat a wide range
      of diseases through activation of the protective arm of the renin-angiotensin system.

      In this study MOR107 will be administered to humans for the first time.

      The study will enroll healthy male subjects and is split into two sequential parts, both of
      which have a single centre, double-blind, randomised, placebo-controlled design.

      Part 1 will evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending
      doses of MOR107.

      Part 2 will evaluate the pharmacodynamics, safety, tolerability and PK of three different
      doses of MOR107 in healthy male subjects who will be fed a low sodium diet in order to
      increase AT2R expression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Part 1 completed successfully. Part 2 not conducted.
  </why_stopped>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Actual">March 23, 2017</completion_date>
  <primary_completion_date type="Actual">March 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1: single ascending doses Part 2: parallel group</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>Up to 10 days post-dose</time_frame>
    <description>Reporting of adverse events, physical examination, injection site assessment, vital signs, ECG, and clinical chemistry, haematology and urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from dosing at which the maximum MOR107 concentration was observed (Tmax)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed MOR107 concentration (Cmax)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of MOR107 at 12 hours post-dose (C12)</measure>
    <time_frame>12 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of MOR107 at 24 hours post-dose (C24)</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 time to last measurable MOR107 concentration (AUC0-t)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 time to infinity for MOR107 (AUC0-inf)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC(0-inf) for MOR107 extrapolated beyond last measured time point (AUC%extrap)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of the apparent elimination phase for MOR107 (Lambda-z)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent elimination half-life for MOR107 (T-half)</measure>
    <time_frame>Up 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOR107 Cmax normalised for dose (Cmax/D)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOR107 AUC(0-t) normalised for dose (AUC[0-t]/D)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOR107 AUC(0-inf) normalised for dose (AUC[0-inf]/D)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Plasma PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of MOR107 excreted in the urine over a specified period of time after dosing (Ae)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Urine PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of MOR107 excreted in the urine (CumAe)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Urine PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of MOR107 excreted in the urine over a specified period of time after dosing, expressed as a percentage of the administered dose (Ae%)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Urine PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of MOR107 excreted in the urine, expressed as a percentage of the administered dose (CumAe%)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Urine PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance: the apparent volume of plasma cleared per unit time via renal elimination (CLr)</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Urine PK parameter</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>Part 1, MOR107 Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR107, single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, MOR107 Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR107, single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, MOR107 Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR107, single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, MOR107 Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR107, single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, MOR107 Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR107, single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, MOR107 Dose level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR107, single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MOR107 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MOR107 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MOR107 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOR107</intervention_name>
    <description>MOR107 solution for injection</description>
    <arm_group_label>Part 1, MOR107 Dose level 1</arm_group_label>
    <arm_group_label>Part 1, MOR107 Dose level 2</arm_group_label>
    <arm_group_label>Part 1, MOR107 Dose level 3</arm_group_label>
    <arm_group_label>Part 1, MOR107 Dose level 4</arm_group_label>
    <arm_group_label>Part 1, MOR107 Dose level 5</arm_group_label>
    <arm_group_label>Part 1, MOR107 Dose level 6</arm_group_label>
    <arm_group_label>Part 2: MOR107 low dose</arm_group_label>
    <arm_group_label>Part 2: MOR107 medium dose</arm_group_label>
    <arm_group_label>Part 2: MOR107 high dose</arm_group_label>
    <other_name>LP2-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for injection manufactured to match MOR107 solution for injection</description>
    <arm_group_label>Part 1, Placebo</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <other_name>Placebo (for MOR107)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low sodium diet</intervention_name>
    <description>Diet designed to restrict sodium intake to 40 mmol/day</description>
    <arm_group_label>Part 2: MOR107 low dose</arm_group_label>
    <arm_group_label>Part 2: MOR107 medium dose</arm_group_label>
    <arm_group_label>Part 2: MOR107 high dose</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Healthy males

          2. Age 18 to 45 years of age

          3. Body mass index of 18.0 to 32.0 kg/m2

          4. For Part 2, subjects must have at least a 25% reduction in 24 hour urinary sodium
             excretion on Day -2 compared with admission

        Key Exclusion Criteria:

          1. Subjects who have received any IMP in a clinical research study within the previous
             three months

          2. Regular alcohol consumption &gt;21 units per week (1 unit = Â½ pint beer, 25 mL of 40%
             spirit or a 125 mL glass of wine)

          3. Current smokers and those who have smoked within the last 12 months. A breath carbon
             monoxide reading of greater than 10 ppm at screening/admission

          4. Current smokers of e-cigarettes and nicotine replacement products and those who have
             smoked these products within the last 12 months

          5. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by
             the investigator

          6. Positive drugs of abuse test result

          7. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

          8. History of psychiatric disorder, cardiovascular, renal, hepatic, chronic respiratory
             or gastrointestinal disease as judged by the investigator

          9. Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Mescheder, MD</last_name>
    <role>Study Director</role>
    <affiliation>LanthioPep BV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>LanthioPep BV</investigator_affiliation>
    <investigator_full_name>Alan Richardson</investigator_full_name>
    <investigator_title>Clinical Project Manager</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

